Avid Bioservices (CDMO) director Sargen acquired 26,756 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Gregory Sargen (director at Avid Bioservices Inc., CDMO) reported that they acquired 26,756 shares on Dec 14, 2024. After these transactions the filing shows 36,368 shares held directly.
- Reporting person
- Sargen Gregory
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 14, 2024 | Exercise or conversion of a derivative (M) | Common Stock, $0.001 par value1 | +26,756 | - | - | 36,368 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 14, 2024 | Exercise or conversion of a derivative (M) | Restricted Stock UnitsOn 26,756 Common Stock1, 2 | -26,756 | - | - | 0 direct |
| Dec 14, 2024 | Grant or award (A) | Restricted Stock UnitsOn 8,147 Common Stock1, 3, 4 | +8,147 | - | - | 8,147 direct |
Holdings before and after
- Common Stock, $0.001 par value: 9,612 to 36,368 direct
- Restricted Stock Units: 26,756 to 8,147 direct
Footnotes from the filing
- 1. Each restricted stock unit ( RSU ) represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock.
- 2. RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024.
- 3. Annual equity award grant pursuant to the Issuer's non-employee director compensation program.
- 4. RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Sargen report in this CDMO Form 4?
Gregory Sargen (director at Avid Bioservices Inc., CDMO) reported that they acquired 26,756 shares on Dec 14, 2024. After these transactions the filing shows 36,368 shares held directly.
How many CDMO shares does Sargen hold after this filing?
The filing shows 36,368 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for CDMO
Earlier insider filings at CDMO
- Dec 18, 2024Director Mackey Catherine J converted options into 26,756 shares, increasing direct ownership by 161% to 43,379 units (SEC Form 4)
- Dec 18, 2024Director Hancock Richard B converted options into 26,756 shares, increasing direct ownership by 23% to 144,319 units (SEC Form 4)
- Dec 18, 2024Director Carleone Joseph converted options into 26,756 shares, increasing direct ownership by 26% to 130,324 units (SEC Form 4)
- Dec 18, 2024Director Alegria Esther M. converted options into 26,756 shares, increasing direct ownership by 243% to 37,746 units (SEC Form 4)
- Oct 15, 2024Chief Commercial Officer Kwietniak Matthew R. converted options into 335 shares and sold $1,208 worth of shares (119 units at $10.15), increasing direct ownership by 0.86% to 25,407 units (SEC Form 4)
Quantisnow market dataNASDAQ
CDMO
Avid Bioservices Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for CDMO
Full CDMO profile on Quantisnow Follow CDMO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time